Holen Sie sich die Stockscreener-App
22.60
2.31%
0.51
Handel nachbörslich:
22.15
-0.45
-1.99%
Acadia Pharmaceuticals Inc Aktie (ACAD) Neueste Nachrichten
ACADIA Pharmaceuticals (ACAD) Stock Could Be 23.2% Undervalued After Guidance Reaffirmed - simplywall.st
ACADIA Pharmaceuticals Inc (ACAD) Institutional Confidence - TradingKey
ACADIA Pharmaceuticals Inc (ACAD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
ACADIA Pharmaceuticals strategy under review, shares tracked against biotech peers - AD HOC NEWS
ACADIA Pharmaceuticals: The Song Remains The Same (NASDAQ:ACAD) - Seeking Alpha
ACADIA Pharmaceuticals Inc (ACAD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Aardvark Therapeutics Becomes Next Pharma Player To Quit Prader-Willi Syndrome Drug Development Efforts - Stocktwits
How Investors May Respond To ACADIA Pharmaceuticals (ACAD) ESOP-Linked Shelf Registration And Potential Dilution - simplywall.st
ACADIA Pharmaceuticals Inc (ACAD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
ACADIA Pharmaceuticals Inc (ACAD) Valuation: PE, PB & Fair Value Analysis - TradingKey
ACADIA Pharmaceuticals Inc (ACAD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
ACADIA Pharmaceuticals Inc (ACAD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
ACADIA Pharmaceuticals Inc - TradingKey
ACADIA Pharmaceuticals Inc (ACAD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Precision Trading with Acadia Pharmaceuticals Inc. (ACAD) Risk Zones - Stock Traders Daily
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Parkinson’s Support Group Meeting Friday, June 12, In Warsaw - InkFreeNews.com
ACADIA Pharmaceuticals stock (US0042251084): earnings momentum and pipeline focus in neuroscience - AD HOC NEWS
Acadia Pharma Must Face Investors' Drug Approval Claims - Law360
A Look At ACADIA Pharmaceuticals (ACAD) Valuation As Shares Show Mixed Recent Momentum - simplywall.st
ACADIA Pharmaceuticals stock (US0042251084): focus on Neurology and rare disease pipeline after late - AD HOC NEWS
A Look At ACADIA Pharmaceuticals (ACAD) Valuation After Recent Share Price Weakness - Yahoo Finance
ACADIA Pharmaceuticals spotlights Alzheimer's psychosis pipeline, NUPLAZID and DAYBUE growth - MSN
Earnings call transcript: ACADIA Pharmaceuticals misses Q1 2026 EPS forecast - Investing.com
Acadia Pharmaceuticals Inc (ACAD) News, Articles, Events & Latest Updates - Stocktwits
ACADIA Pharmaceuticals earnings up next: Can drug sales sustain momentum? - Investing.com
ACADIA Stock Climbs After Hours as Biotech Rally Shifts Focus to Its Next Big Drug Readout - Bez Kabli
ACAD Technical Analysis | Trend, Signals & Chart Patterns | ACADIA PHARMACEUTICALS INC (NASDAQ:ACAD) - ChartMill
Baker funds tied to ACAD (ACAD) report RSU and stock option grants - Stock Titan
Technical Reactions to ACAD Trends in Macro Strategies - Stock Traders Daily
ACAD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ACADIA Pharmaceuticals (ACAD) director receives new RSUs and stock option grant - Stock Titan
ACADIA (NASDAQ: ACAD) director Adora Ndu exercises RSUs and receives new option, RSU grants - Stock Titan
ACADIA (NASDAQ: ACAD) director receives RSUs and $21.66 stock options - Stock Titan
ACADIA (NASDAQ: ACAD) director granted RSUs, options and exercises into shares - Stock Titan
ACADIA (ACAD) director Garofalo exercises RSUs and receives new option, RSU awards - Stock Titan
ACADIA (NASDAQ: ACAD) director granted RSUs and stock options - Stock Titan
Acadia Shareholders Approve Directors, Executive Pay and Equity Plan - The Globe and Mail
A Quick Look at Today's Ratings for ACADIA Pharmaceuticals(ACAD.US), With a Forecast Between $24 to $38 - Moomoo
Acadia Pharmaceuticals (NASDAQ: ACAD) investors approve 5.2M-share boost to 2024 equity plan - Stock Titan
Principal Accounting Officer At ACADIA Pharmaceuticals Sells $114K Of Stock - Benzinga
Biopharmas look to China, elsewhere for partnerships, R&D - MSN
Insider Sell: James Kihara Sells Shares of ACADIA Pharmaceuticals Inc (ACAD) - GuruFocus
Acadia principal accounting officer Kihara sells $114,393 stock - Investing.com UK
[Form 4] ACADIA PHARMACEUTICALS INC Insider Trading Activity - Stock Titan
ACADIA Pharmaceuticals (ACAD) Holds Near Support as Price Action ConsolidatesDiagonal Spread Trade - thelegaladvocate.com
ACADIA Pharmaceuticals targets $1B brand opportunity as key neuropsychiatry data looms - MSN
Form 144 lists 3,857 performance shares and ESPP lots for ACAD (NASDAQ: ACAD) - Stock Titan
Acadia Pharmaceuticals (ACAD) lags Q1 earnings and revenue estimates - MSN
Acadia boosts ‘More To Parkinson's’ campaign with Ryan Reynolds, Parkinson’s voices - Fierce Pharma
Acadia Pharmaceuticals’ SWOT analysis: stock faces EU hurdle By Investing.com - Investing.com Canada
0.48%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):